Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

File Type:

PDF

Item Type:

Journal Article

Date:

2018

Author:

O'Byrne, Ken

Access:

openAccess

Citation:

Wu, Y.-L. and Sequist, L.V. and Tan, E.-H. and Geater, S.L. and Orlov, S. and Zhang, L. and Lee, K.H. and Tsai, C.-M. and Kato, T. and Barrios, C.H. and Schuler, M. and Hirsh, V. and Yamamoto, N. and O'Byrne, K. and Boyer, M. and Mok, T. and Peil, B. and M??rten, A. and Chih-Hsin Yang, J. and Paz-Ares, L. and Park, K., Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials, Clinical Lung Cancer, 19, 4, 2018, e465-e479

Download Item:

  (1-s2.0-S1525730418300512-main.pdf)  798.4Kb

URI:

http://hdl.handle.net/2262/85084

Author's Homepage:

http://people.tcd.ie/obyrneke

Author: O'Byrne, Ken

Type of material:

Journal Article

URI:

http://hdl.handle.net/2262/85084

Collections

• Clinical Medicine (Scholarly Publications)
• RSS Feeds

Series/Report no:

Clinical Lung Cancer;
19;
4;

Availability:

Full text available

Keywords:

Afatinib

DOI:

http://dx.doi.org/10.1016/j.cllc.2018.03.009

Metadata

Show full item record